Cargando…
Biomarkers of chondrosarcoma
Clinical outcome prediction is major concern to patients with cancer. Various molecular markers in various carcinomas have been identified in the past few decades. However, accurate predictors in chondrosarcoma have not been developed, even though chondrosarcoma is the second most common primary bon...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204964/ https://www.ncbi.nlm.nih.gov/pubmed/29593061 http://dx.doi.org/10.1136/jclinpath-2018-205071 |
_version_ | 1783366120347009024 |
---|---|
author | Jeong, Wonju Kim, Ha-Jeong |
author_facet | Jeong, Wonju Kim, Ha-Jeong |
author_sort | Jeong, Wonju |
collection | PubMed |
description | Clinical outcome prediction is major concern to patients with cancer. Various molecular markers in various carcinomas have been identified in the past few decades. However, accurate predictors in chondrosarcoma have not been developed, even though chondrosarcoma is the second most common primary bone tumour. Chondrosarcoma is the cartilage-forming malignancy and shows a wide spectrum of clinicopathological behaviours. The majority of chondrosarcoma grows slowly and rarely metastasises, and adequate surgery leads to a good prognosis. However, wide surgical excision is acquired in high-grade chondrosarcoma, because this tumour is highly resistant to chemotherapy and radiotherapy. To decide best therapy, accurate diagnostic markers are also necessary in chondrosarcoma. It is reported that angiogenesis and lymphangiogenesis increase by chondrosarcoma staging, and they are promoted by leptin and adiponectin. Several microRNAs to regulate vascular endothelial growth factor (VEGF)-A and VEGF-C are also reported. Alpha-methylacyl-CoA racemase and periostin are proposed as new biomarkers for differential diagnosis of enchondroma and chondrosarcoma. This review summarises that chondrosarcoma diagnostic markers are currently reported. |
format | Online Article Text |
id | pubmed-6204964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-62049642018-11-08 Biomarkers of chondrosarcoma Jeong, Wonju Kim, Ha-Jeong J Clin Pathol Review Clinical outcome prediction is major concern to patients with cancer. Various molecular markers in various carcinomas have been identified in the past few decades. However, accurate predictors in chondrosarcoma have not been developed, even though chondrosarcoma is the second most common primary bone tumour. Chondrosarcoma is the cartilage-forming malignancy and shows a wide spectrum of clinicopathological behaviours. The majority of chondrosarcoma grows slowly and rarely metastasises, and adequate surgery leads to a good prognosis. However, wide surgical excision is acquired in high-grade chondrosarcoma, because this tumour is highly resistant to chemotherapy and radiotherapy. To decide best therapy, accurate diagnostic markers are also necessary in chondrosarcoma. It is reported that angiogenesis and lymphangiogenesis increase by chondrosarcoma staging, and they are promoted by leptin and adiponectin. Several microRNAs to regulate vascular endothelial growth factor (VEGF)-A and VEGF-C are also reported. Alpha-methylacyl-CoA racemase and periostin are proposed as new biomarkers for differential diagnosis of enchondroma and chondrosarcoma. This review summarises that chondrosarcoma diagnostic markers are currently reported. BMJ Publishing Group 2018-07 2018-03-28 /pmc/articles/PMC6204964/ /pubmed/29593061 http://dx.doi.org/10.1136/jclinpath-2018-205071 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Review Jeong, Wonju Kim, Ha-Jeong Biomarkers of chondrosarcoma |
title | Biomarkers of chondrosarcoma |
title_full | Biomarkers of chondrosarcoma |
title_fullStr | Biomarkers of chondrosarcoma |
title_full_unstemmed | Biomarkers of chondrosarcoma |
title_short | Biomarkers of chondrosarcoma |
title_sort | biomarkers of chondrosarcoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204964/ https://www.ncbi.nlm.nih.gov/pubmed/29593061 http://dx.doi.org/10.1136/jclinpath-2018-205071 |
work_keys_str_mv | AT jeongwonju biomarkersofchondrosarcoma AT kimhajeong biomarkersofchondrosarcoma |